- Bitget PoolX is listing Squid (QUID): Lock XAUT and QUID to get 860,000 QUID airdrop
- Spot silver has just reached the $62.00/oz mark, now quoted at $62.00/oz, up 4.21% on the day; main COMEX silver futures are now quoted at $62.26/oz, up 3.34% on the day.
- Spot gold has just broken through the $4,190.00/oz mark, now quoted at $4,190.08/oz, up 2.77% on the day; COMEX gold futures main contract is now quoted at $4,249.60/oz, up 2.34% on the day.
- SpaceX Surprises Wall Street With Better-than-expected Results
- XRP Collateral Supply Shock Loading. Here’s What Is Happening
- Bitcoin lags as global equities reach record highs
- Pump.fun buys back 332M PUMP – Rally continues ONLY IF…
- Visa expands stablecoin capabilities on Visa Direct with zerohash collaboration
- CandyBomb x QUID: Trade to share 120,000 USDT
- Avnet 4Q EPS $1.49 >AVT
- B&G Foods Announces Retirement Of CEO And Selection Of Successor >BGS
- Global Ship Lease 2Q Rev $198.7M >GSL
- Avnet 4Q Adj EPS $2.28 >AVT
- SmartRent 2Q Loss $5.64M >SMRT
- Icahn Enterprises 2Q Loss/Shr 52c >IEP
- US Dollar: Consolidation view into ISM and payrolls – BBH
- The long-term US Treasury yields continue to decline as the market bets on the implementation of the Hormuz Agreement.
- Shopify (SHOP.US) shares rose 33.8% in U.S. pre-market trading after its third-quarter revenue outlook exceeded market expectations. Shopify stated that it expects its revenue to achieve a "growth rate in the low 30% range." This rate will surpass Wall Street's previous expectation of 27% and means the company's revenue growth will exceed 30% for six consecutive quarters. Analyst Anurag Rana noted in a report that rising artificial intelligence costs were initially expected to compress profit m
- Brent: Price slips on Hormuz deal hopes – Rabobank
- Palantir Stock Rallies 30% and Its CEO Climbs Forbes Billionaire Ranking
- Novo Nordisk (NVO.US): The price dynamics of the Wegovy injection in the United States remain the same as at the beginning of the year.
- Spot silver rose 4.00% intraday to $61.88 per ounce; the main COMEX silver futures contract is now at $62.17 per ounce, up 3.20% on the day.
- Circle Q2 revenue falls short of Wall Street estimates
- Bitcoin ETF inflows hit $381M – Could BTC end its August losing streak?
- 3 Top Altcoins Primed for a MEGA PUMP (ISO 20022 Compliant)
- New York Times Posts Higher 2Q Revenue, as Subscriber Growth Slows
- Spot platinum has just surpassed the $1,760.00/oz mark, now quoted at $1,760.55/oz, up 1.59% on the day; Nymex platinum futures main contract is now quoted at $1,774.6/oz, up 1.06% on the day.
- Stack Capital Group 2Q Total Book Value C$313M >STCK.T
- Stack Capital Group 2Q Book Value Per Share C$20.25 >STCK.T
- Aurora Cannabis 1Q Loss Narrows Despite Fall in Revenue
- Gibraltar Industries Backs 2026 EPS $2.40-EPS $2.80 >ROCK
- InPlay Oil in Definitive Agreement to Acquire Private Oil and Gas Producer for Cash Consideration of C$54.25M >IPO.T
- Gibraltar Industries Backs 2026 Sales $1.76B-$1.83B >ROCK
- XPEL Sees 3Q Rev $137M-$139M >XPEL
- Gibraltar Industries 2Q Cont Ops EPS 92c >ROCK
- Griffon 3Q EPS $1.14 >GFF
- Griffon 3Q Adj EPS $1.51 >GFF
- EVgo Sees FY26 Rev $400M-$430M >EVGO
- Bioventus Backs 2026 Adj EPS 75c-Adj EPS 79c >BVS
- Medline 2Q Net $139M >MDLN
- Medline 2Q EPS 7c >MDLN
- Gibraltar Industries 2Q Adj EPS $1.11 >ROCK
- Medline 2Q Sales $7.69B >MDLN
- Bioventus 2Q Adj EPS 22c >BVS
- Immuneering Expects Cash Runway to Be Sufficient to Fund Ops Into 2029 >IMRX
- Bioventus Backs 2026 Sales $600M-$610M >BVS
- Bioventus 2Q Sales $153.2M >BVS
- Bioventus 2Q EPS 47c >BVS
- Immuneering 2Q Loss/Shr 27c >IMRX
- BorgWarner Sees FY Sales $14B-$14.3B >BWA
- CVS Health 2Q Same-Store Sales Up 2.6% >CVS
- CVS Health 2Q Pharmacy Same-Store Sales Up 2.9% >CVS
- CVS Health 2Q Health Services Segment Revenue $51.8B >CVS
- CVS Health 2Q Healthcare Benefits Segment Revenue Up 3.5% >CVS
- CVS Health 2Q Health Services Segment Revenue Up 11.5% >CVS
- CVS Health Raises 2026 View To Adj EPS $7.90-Adj EPS $8.10 Vs Prior Guidance $7.30-$7.50 >CVS
- CVS Health 2Q Pharmacy & Consumer Wellness Segment Revenue Rose Slightly >CVS
- CVS Health: 2Q Adjusted EPS Rose Primarily Due to Improved Adjusted Operating Income in Health Care Benefits Segment >CVS
- CVS Health: 2Q Health Care Benefits Segment Rev Rose Primarily Driven by Increase in Govt Business, Partially Offset by Decline as Result of CO's Exit of Individual Exchange Business in 2026 >CVS
- CVS Health: 2Q Health Services Segment Rev Rose Primarily Driven by Pharmacy Drug Mix and Brand Inflation, Partially Offset by Continued Pharmacy Client Price Improvements >CVS
- CVS Health 2Q Same-Store Prescription Volume Rose 7% >CVS
- CVS Health 2Q Prescriptions Filled Rose 4.3% on 30-Day Equivalent Basis >CVS
- CVS Health Health Care Benefits Segment's 2Q Medical Benefit Ratio 87.4% >CVS
- CVS Health Increasing Full-Year 2026 EPS, Adj EPS and Cash Flow From Operations Guidance to Reflect Increases in Health Care Benefits and Pharmacy & Consumer Wellness Segments >CVS
- CVS Health Sees 2026 Total Revenue of at Least $414B >CVS
- CVS Health Updates 2026 Cash Flow From Operations Guidance to at Least $11.5B From at Least $9.5B >CVS
- CVS Health: Enhances Direct-To-Consumer Weight Management Offerings to Improve Access, Affordability, Care and Support for GLP-1 Medications >CVS
- CVS Health: New Collaboration With Eli Lilly Will Provide Eligible Zepbound and Foundayo Patients Additional Access Point at CVS Pharmacy Through CVS Health App >CVS
- CVS Health 2Q Rev $106.1B >CVS
- Delek Logistics Partners 2Q EPS 54c >DKL
- NiSource Sees FY Adj EPS $2.02-Adj EPS $2.07 >NI
- NiSource 2Q Net $45.5M >NI
- BorgWarner Sees FY Adj EPS $5.05-Adj EPS $5.30 >BWA
- BorgWarner 2Q Net $277M >BWA
- BorgWarner 2Q Adj EPS $1.42 >BWA
- BorgWarner Reports Strong Second Quarter 2026 Results, Increases 2026 Adjusted EPS Guidance And Share Repurchase Authorization By $1 Billion, And Announces 7 Awards Across Portfolio To Support Long-Term Profitable Growth >BWA
- CVS Health 2Q Same-Store Sales Up 2.6% >CVS
- CVS Health 2Q Pharmacy Same-Store Sales Up 2.9% >CVS
- CVS Health 2Q Front Store Same-Store Sales Up 1.0% >CVS
- CVS Health 2Q Net $2.98B >CVS
- CVS Health Raises 2026 View To EPS $6.84-EPS $7.04 Vs Prior Guidance $6.24-$6.44 >CVS
- CVS Health 2Q EPS $2.31 >CVS
- Delek US 2Q EPS $2.71 >DK
- BorgWarner 2Q EPS $1.34 >BWA
- BorgWarner Sees FY EPS $4.72-EPS $4.94 >BWA
- Dynatrace 1Q EPS 12c >DT
- Edgewell Personal Care Adjusts 2026 View To EPS 0c-EPS 20c >EPC
- Ecovyst Previous Adj EBITDA Guidance Was $180M$>ECVT
- Ridgepost Capital 2Q Adj EPS 24c >RPC
- Primo Brands 2Q Adj EPS 37c >PRMB
- Ridgepost Capital 2Q EPS 6c >RPC
- Ecovyst Raises 2026 Adjusted EBITDA to $195M- $207M >ECVT
- Ecovyst: Previous Sales Guidance Was $890M$>ECVT
- Louisiana-Pacific Sees 3Q Siding Net Sales $460M-$470M >LPX
- Correct: Ecovyst: Previous Sales Guidance Was $890M-$970M >ECVT
- Northwest Natural 2026 EPS Seen in Upper Half of Guidance Range of $2.95-$3.15 >NWN
- Louisiana-Pacific Sees 2026 Siding Net Sales $1.65B-$1.67B >LPX
- Edgewell Personal Care Narrows 2026 Reported Net Sales to Up 1.3%-1.8%>EPC
- Primo Brands Sees 2026 Net Sales Growth of 2%-4% >PRMB
- Primo Brands 2Q EPS 19c >PRMB
